Literature DB >> 26755264

Liver.

W R Kim1,2, J R Lake2,3, J M Smith2,4, M A Skeans2, D P Schladt2, E B Edwards5,6, A M Harper5,6, J L Wainright5,6, J J Snyder2,7, A K Israni2,7,8, B L Kasiske2,8.   

Abstract

The median waiting time for patients with MELD ≥ 35 decreased from 18 days in 2012 to 9 days in 2014, after implementation of the Share 35 policy in June 2013. Similarly, mortality among candidates listed with MELD ≥ 35 decreased from 366 per 100 waitlist years in 2012 to 315 in 2014. The number of new active candidates added to the pediatric liver transplant waiting list in 2014 was 655, down from a peak of 826 in 2005. The number of prevalent candidates (on the list on December 31 of the given year) continued to decline, 401 active and 173 inactive. The number of deceased donor pediatric liver transplants peaked at 542 in 2008 and was 478 in 2014. The number of living donor liver pediatric transplants was 52 in 2014; most were from donors closely related to the recipients. Graft survival continued to improve among pediatric recipients of deceased donor and living donor livers. © Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  Liver transplant; model for end-stage liver disease; waiting list

Mesh:

Substances:

Year:  2016        PMID: 26755264     DOI: 10.1111/ajt.13668

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  28 in total

1.  Analysis of Liver Offers to Pediatric Candidates on the Transplant Wait List.

Authors:  Evelyn K Hsu; Michele L Shaffer; Lucy Gao; Christopher Sonnenday; Michael L Volk; John Bucuvalas; Jennifer C Lai
Journal:  Gastroenterology       Date:  2017-07-13       Impact factor: 22.682

Review 2.  Considerations When Treating Hepatitis C in a Cirrhotic Transplant Candidate.

Authors:  Kimberly E Daniel; Adnan Said
Journal:  Curr Gastroenterol Rep       Date:  2018-04-05

3.  New Therapies for Hepatitis C Virus Infection.

Authors:  Jennifer L Horsley-Silva; Hugo E Vargas
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-01

Review 4.  Could there be light at the end of the tunnel? Mesocaval shunting for refractory esophageal varices in patients with contraindications to transjugular intrahepatic portosystemic shunt.

Authors:  Jessica Davis; Albert K Chun; Marie L Borum
Journal:  World J Hepatol       Date:  2016-07-08

5.  What patients and members of their support networks ask about transplant program data.

Authors:  Cory R Schaffhausen; Marilyn J Bruin; Daryl Chesley; Maureen McBride; Jon J Snyder; Bertram L Kasiske; Ajay K Israni
Journal:  Clin Transplant       Date:  2017-10-23       Impact factor: 2.863

6.  Share 35 changes in center-level liver acceptance practices.

Authors:  David S Goldberg; Matthew Levine; Seth Karp; Richard Gilroy; Peter L Abt
Journal:  Liver Transpl       Date:  2017-05       Impact factor: 5.799

7.  When a liver transplant recipient goes back to alcohol abuse: Should we be more selective?

Authors:  Monica Leon; Joseph Varon; Salim Surani
Journal:  World J Gastroenterol       Date:  2016-05-28       Impact factor: 5.742

Review 8.  Selection of Patients for Initial Clinical Trials of Solid Organ Xenotransplantation.

Authors:  David K C Cooper; Martin Wijkstrom; Sundaram Hariharan; Joshua L Chan; Avneesh Singh; Keith Horvath; Muhammad Mohiuddin; Arielle Cimeno; Rolf N Barth; John C LaMattina; Richard N Pierson
Journal:  Transplantation       Date:  2017-07       Impact factor: 4.939

9.  Factors Associated With Short- and Long-term Liver Graft Survival in the United Kingdom: Development of a UK Donor Liver Index.

Authors:  David Collett; Peter J Friend; Christopher J E Watson
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

10.  Changes in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era.

Authors:  M G Bowring; L M Kucirka; A B Massie; X Luo; A Cameron; M Sulkowski; K Rakestraw; A Gurakar; I Kuo; D L Segev; C M Durand
Journal:  Am J Transplant       Date:  2016-08-24       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.